Last updated: April 15, 2026
What is MYLAXEN?
MYLAXEN is a pharmaceutical product approved for the treatment of functional bowel disorders, primarily used as a laxative. It contains the active ingredient prucalopride, a selective 5-HT4 receptor agonist that increases gastrointestinal motility. It was approved in multiple markets, including the US and Europe, starting in 2014.
Market Size and Growth
Global Market Overview
The global laxative market was valued at approximately $2.1 billion in 2022. It is projected to reach $2.8 billion by 2028, with compound annual growth rate (CAGR) around 4.6%. The growth derives from increasing prevalence of constipation, especially among aging populations, and expanding indications for laxatives like MYLAXEN.
| Year |
Market Size (USD billion) |
CAGR |
Source |
| 2022 |
2.1 |
- |
[1] |
| 2028 |
2.8 |
4.6% |
[1] |
MYLAXEN Positioning
MYLAXEN accounts for a specific segment within this market, with a focus on chronic constipation and irritable bowel syndrome with constipation (IBS-C). Its unique mechanism of action targets patients who do not respond to traditional laxatives.
Market penetration has grown steadily. In 2022, MYLAXEN held approximately 12% of the prescription laxative segment in the US, with anticipated growth to 18% by 2028.
Competitive Landscape
Key Competitors
- Lubiprostone (Amitiza)
- Linaclotide (Linzess)
- Plecanatide (Trulance)
- Senna-based OTC products
Differentiation
MYLAXEN's prucalopride offers advantages in pharmacodynamics, including a longer half-life (about 24 hours), allowing once-daily dosing. Its safety profile is well-documented, with side effects mainly gastrointestinal or headache.
Competitive Risks
- Market entry of biosimilar or generics.
- Regulatory updates affecting chronic use.
- Competition from non-prescription remedies.
Regulatory and Distribution Mechanics
Approvals and Indications
- US FDA approval in 2014 for chronic idiopathic constipation in women.
- EMA approval in 2013 for adults with chronic constipation.
Market Access Strategies
Manufacturers have pursued partnerships with major pharmacy chains and payers to facilitate coverage. Reimbursement policies vary, with key markets requiring prior authorization for chronic indications.
Financial Trajectory
Revenue Growth
From initial launch through 2022, MYLAXEN's global sales increased at a CAGR of approximately 15%, driven primarily by the US and European markets.
| Year |
Estimated Revenue (USD millions) |
Notes |
| 2014 |
50 |
Launch year |
| 2018 |
150 |
Market expansion |
| 2022 |
300 |
Peak of recorded sales |
Projection Analysis
Assuming steady growth, sales are projected to reach USD 500 million by 2027, with regional expansion into Asia-Pacific and Latin America. Growth is constrained by competition and regulatory delays in some markets.
Profitability Metrics
Gross margins are estimated at 70%, influenced by manufacturing costs and patent protections. R&D expenses account for about 15% of revenue, focused on new formulations and expanding indications.
Regulatory Challenges and Opportunities
- Patent protection expires in key territories from 2030, risking generic competition.
- Ongoing clinical trials are exploring additional indications, including pediatric constipation and opioid-induced constipation.
- Potential for labeling expansions could significantly boost revenues.
Key Market Drivers & Risks
Drivers
- Rising incidence of chronic constipation.
- Aging populations in developed markets.
- Evolving clinical guidelines favoring prokinetic agents.
Risks
- Generic erosion post-patent expiry.
- Regulatory challenges for new indications.
- Market saturation in mature regions.
Conclusion
MYLAXEN's market position reflects steady growth driven by chronic constipation prevalence trends and its efficacy profile. Continued market expansion hinges on regulatory approvals, formulary inclusion, and pipeline development. Its financial trajectory, supported by sustained sales and expanding indications, projects a potential for reaching USD 500 million in revenue in the next five years, barring significant market or regulatory disruptions.
Key Takeaways
- The global laxative market is forecasted to grow at 4.6% CAGR to USD 2.8 billion by 2028.
- MYLAXEN maintains a growing market share, with US prescriptions constituting a primary revenue driver.
- Revenue growth from 2014 to 2022 averaged 15% annually, with projections indicating continued expansion.
- Patent expiration around 2030 could impact profitability; pipeline development is vital.
- Competitive landscape features multiple novel agents and OTC options influencing market dynamics.
FAQs
1. What factors influence MYLAXEN’s market share?
Market penetration depends on prescription volume, physician adoption, formulary placement, and regulatory decisions.
2. How does MYLAXEN's efficacy compare to competitors?
Clinical trials show similar or superior efficacy in IBS-C and chronic constipation, with a favorable side-effect profile.
3. What risks exist around patent expiry?
Generic entry post-2030 could lead to significant revenue reductions if not offset by pipeline products.
4. Are there upcoming regulatory approvals for new indications?
Clinical trials are ongoing for pediatric use and opioid-induced constipation, with potential approval timelines extending beyond 2024.
5. Which markets present the most growth opportunities?
Asia-Pacific and Latin America currently have lower penetration but higher growth potential due to increasing awareness and healthcare infrastructure investments.
References
[1] MarketWatch. (2023). Laxative Market Size and Forecast. MarketWatch.
